Axonis Therapeutics: Valuation, Funding & Investors
Axonis Therapeutics is a biotechnology company dedicated to developing innovative neuromedicines, particularly first-in-class therapies for neurological disorders. The company's lead candidate, AXN-027, is an oral small molecule aimed at enhancing the function of KCC2, a key CNS chloride transporter, to treat conditions such as epilepsy and pain. Additionally, Axonis is focused on advancing next-generation compounds targeting KCC2 for various neurological, psychiatric, and neurodevelopmental disorders.
Leadership & Board
- Current Number of Employees
- 29
- Current LinkedIn Followers
- 6,693
Latest Estimated Valuation
- Total Amount Raised
- $115M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $115M
- Latest Funding Round
- Series A
Employee Trend
Axonis Therapeutics had 29 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Axonis Therapeutics had 6,693 followers as of November 16, 2026. The number of followers increased by 42 (0.63%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Aug 14, 2025 | Series A | $115.00M | ― |
Similar Companies
A snapshot of private companies similar to Axonis Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis








